Edesa Biotech’s Paridiprubart Reduces Mortality in Phase III ARDS Trial

Edesa Biotech has reported positive Phase III results for its investigational therapy paridiprubart (EB05) in acute respiratory distress syndrome (ARDS). The drug met its primary endpoint, achieving a significant reduction in 28-day mortality in the intention-to-treat population. Patients receiving paridiprubart plus standard of care (SOC) had a 39% mortality rate, versus 52% with placebo, reflecting a 13% absolute improvement and a 25% relative risk reduction.

At 60 days, survival benefits persisted, with 46% mortality in the paridiprubart group compared to 59% for placebo, representing another 13% absolute survival gain. The therapy also led to a 41% higher clinical improvement rate, with more patients no longer requiring organ support or invasive mechanical ventilation by day 28.

Across 275 participants, the drug was well tolerated, supporting its potential as a new standard of care for ARDS and future chronic respiratory indications.

02-11-2025